SCF/c-kit Ligand Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27162
Key Product Details
Species Reactivity
Validated:
Human
Predicted:
Mouse (100%). Backed by our 100% Guarantee.
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
A synthetic peptide corresponding to amino acids 121-158 of mouse kitl was used as immunogen, GenBank no gb|AAA39378.1|.
Reactivity Notes
The amino acid sequence used as immunogen is 100% homologous in mouse and 77% homologous in rat.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for SCF/c-kit Ligand Antibody
Western Blot: SCF/c-kit Ligand Antibody [NBP2-27162]
Western Blot: SCF/c-kit Ligand Antibody [NBP2-27162] - Analysis of SCF in mouse liver lysate in the 1) absence and 2) presence of immunizing peptide using this antibody at 4 ug/ml. Goat anti-rabbit Ig HRP secondary antibody and PicoTect ECL substrate solution were used for test.Applications for SCF/c-kit Ligand Antibody
Application
Recommended Usage
Western Blot
3-5ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
0.2 ml PBS and 0.05% BSA
Preservative
0.05% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: SCF/c-kit Ligand
Long Name
Stem Cell Factor
Alternate Names
c-kit Ligand, DCUA, DFNA69, FPH2, FPHH, KITLG, KL-1, MGF, SHEP7, SLF
Gene Symbol
KITLG
Additional SCF/c-kit Ligand Products
Product Documents for SCF/c-kit Ligand Antibody
Product Specific Notices for SCF/c-kit Ligand Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...